Abstract
The hypoxic microenvironment is a clinicopathological characteristic of many diseases, such as rheumatoid arthritis (RA). As a transcription factor activating the gene expression involved in processes such as cell metabolism and angiogenesis, hypoxia-inducible factor (HIF) has a central function in adaption to altered oxygen tension and even contributes to the progression of related diseases. In RA, HIF induces angiogenesis, cell migration, and cartilage destruction, inhibits the apoptosis of synovial cells and inflammatory cells and initiates glycolysis for energy supply by upregulating specific protein levels. HIF expression in RA can be regulated in both oxygen-dependent and independent fashions, leading to the aggravation of this disease. Therefore, HIF is one of the vital RA mediators. Based on the application of HIFtargeted drug research and development in tumors, HIF is a potential therapeutic target for treating RA.
Keywords: Angiogenesis, hypoxia-inducible factor, rheumatoid arthritis, regulation, tumor therapy, therapeutic target.
Current Drug Targets
Title:Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis
Volume: 14 Issue: 6
Author(s): Xuli Zhao, Ye Yue, Wengxiang Cheng, Jingchao Li, Yiping Hu, Ling qin and Peng Zhang
Affiliation:
Keywords: Angiogenesis, hypoxia-inducible factor, rheumatoid arthritis, regulation, tumor therapy, therapeutic target.
Abstract: The hypoxic microenvironment is a clinicopathological characteristic of many diseases, such as rheumatoid arthritis (RA). As a transcription factor activating the gene expression involved in processes such as cell metabolism and angiogenesis, hypoxia-inducible factor (HIF) has a central function in adaption to altered oxygen tension and even contributes to the progression of related diseases. In RA, HIF induces angiogenesis, cell migration, and cartilage destruction, inhibits the apoptosis of synovial cells and inflammatory cells and initiates glycolysis for energy supply by upregulating specific protein levels. HIF expression in RA can be regulated in both oxygen-dependent and independent fashions, leading to the aggravation of this disease. Therefore, HIF is one of the vital RA mediators. Based on the application of HIFtargeted drug research and development in tumors, HIF is a potential therapeutic target for treating RA.
Export Options
About this article
Cite this article as:
Zhao Xuli, Yue Ye, Cheng Wengxiang, Li Jingchao, Hu Yiping, qin Ling and Zhang Peng, Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis, Current Drug Targets 2013; 14 (6) . https://dx.doi.org/10.2174/1389450111314060010
DOI https://dx.doi.org/10.2174/1389450111314060010 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemical Inhibition of Matrix Metalloproteinases for Periodontal Treatment
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Natural Anticoagulant Proteins in the Regulation of Autoimmunity: Potential Role of Protein S
Current Pharmaceutical Design Resistance to Anti-VEGF Agents
Current Pharmaceutical Design Insights into Targeting NEMO for Pharmacological Regulation
Current Drug Targets Natural Products Containing Olefinic Bond: Important Substrates for Semi-synthetic Modification Towards Value Addition
Current Organic Chemistry Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery Gene Therapy Strategies to Prevent Autoimmune Disorders
Current Gene Therapy Somatic Mosaicism in Cases with Small Supernumerary Marker Chromosomes
Current Genomics Chemical and Biochemical Basis of Cell-Bone Matrix Interaction in Health and Disease
Current Chemical Biology Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Non-Analgesic Effects of Opioids: Opioids’ Effects on Sleep (Including Sleep Apnea)
Current Pharmaceutical Design Relationships between Serotoninergic System and Skin Fibrotic
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets Cytochromes P450 and Skin Cancer: Role of Local Endocrine Pathways
Anti-Cancer Agents in Medicinal Chemistry The Modulating Effects of Endogenous Substances on Drug Metabolising Enzymes and Implications for Inter-Individual Variability and Quantitative Prediction
Current Drug Metabolism Malignancy Risk in Systemic Lupus: Recent Research and Ongoing Challenges
Current Rheumatology Reviews Antioxidant Activity of 1,2,4-Triazole and its Derivatives: A Mini-Review
Mini-Reviews in Medicinal Chemistry Creating A Standard of Care for Fertility Preservation
Current Women`s Health Reviews